Discussion  by unknown
Congenital Heart Disease Nathan et al
C
H
D(those who were<18 years and for whom the RACHS-1
category could not be assigned) also had greater mortality
and adverse events and a longer postoperative ICU length
of stay. This could have been because this group
predominantly consisted of patients who have undergone
more complex procedures, such as biventricular recruitment
in hypoplastic left heart, biventricular conversion after
single ventricle palliation, VADS for end-stage heart
failure, and certain complex heart and lung transplants.Study Limitations
The present study represents a single center’s experience
with validation of the TPS. Testing the reproducibility of
this tool across multiple centers is necessary. Furthermore,
validation of the association of TPS with long-term
outcomes is required. We are in the process of collecting
long-term prospective data for this cohort. Although the
present study included larger numbers of patients in each
of the RACHS-1 categories, ideally, the association
between TPS and early outcomes should be studied in
individual procedural groups. We are currently involved
in a multicenter study to validate the TPS prospectively in
specific procedural groups, and we anticipate that this will
allow us to weight each component of the score and
determine the predictive value of each component. This
information will be particularly important, because it would
allow the TPS to be used as a tool that can help determine
which patient would warrant early intervention to avoid
morbidity.CONCLUSIONS
The TPS has been shown to have a strong association with
early outcomes such as mortality, adverse events, and
increased resource use. It might thus allow the development
of predictors for early intervention for residual anatomic
problems.We speculate that it could lead to an improvement
in the long-term physical, neurologic, and psychosocial
development in this vulnerable high-risk population by
identifying patients who would benefit from early interven-
tion and decrease the burden of prolonged illness on patients
with congenital heart disease and their families.
We would like to acknowledge Emile Bacha, MD, and Kathy
Jenkins, MD, for their contributions to the development of the
technical performance score.References
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Dr Christopher A. Caldarone (Toronto, Ontario, Canada).
My only disclosure is that I am a fan of technical performance
scores.
‘‘Mirror, mirror on the wall, who’s the fairest of them all,’’ so
said the witch. She wanted to know how she stacked up against
her peers. How did her blemishes compare to the blemishes of
others? As surgeons, we all want to know the same. Aside fromery c January 2014
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Dcomparing gross measures of mortality, we have very little ability
to compare the residual lesions we commonly leave behind.
Dr Nathan and her team should be congratulated for extending
the pioneering work of Emile Bacha in developing the concept of
technical performance scores, a systematic approach to identifying
the significance of residual lesions. You have shown us that
residual lesions are common, and they contribute to mortality.
This is a deceptively simple, yet transformative, concept, a mirror
that we all need.
I have a few questions that will focus on a critique of the
method.
First, your team evaluates numerous components for the
surgical procedure and grades each component into 3 categories.
This approach provides simplicity but results in inevitable loss
of important information. Supporting this notion is your finding
that there is very little difference between the adequate and
optimal score categories—suggesting a loss of information by
categorization. Why did you not create a scoring system in which
continuous variables are maintained and derive a score that is itself
a continuous variable? This would avoid potentially sensitive
terms such as ‘‘inadequate’’ and provide greater discrimination
of outcomes.
Second, your methodology includes the laudable concept of
downgrading a technical performance score to match the lowest
component score. This is based on the premise that each
component has equal clinical significance. However, the clinical
significance of 1 residual lesion could be different from another.
How will you refine your scoring system in the future to take
into account the difference in clinical significance of these various
components?
Third, in the current version of your scoring system, when a
region is not addressed by the surgeon, it is not included in the
TPS. Thus, a patient with residual tricuspid insufficiency, for
example, is included in the scoring system if the surgeon addressed
the tricuspid valve but is not included in the scoring system if the
surgeon chose not to address the residual lesion. Although this
approach keeps the scoring system focused on the interventions
of the surgeon, it ignores the effect of untouched residual lesions,
which are of importance to the patient. Dr Nathan, should an
assessment of surgical performance be limited to the subroutines
performed by the surgeon or should performance be determined
by the patient’s overall freedom from residual lesions?
Finally, as you know, the Congenital Heart Surgeons Society, in
collaboration with members of your team, has developed a web-
based data entry system to provide a technical performance
‘‘mirror’’ for our participants. This system will provide new
information for us to improve our patient care, but it is not clear
how we will transform the concept of a TPS into improved
outcomes. How do you distribute, discuss, and use TPS in Boston
to improve patient outcomes? I want to thank the Association for
the privilege to discuss this study.
Dr Nathan. Thank you, Dr Caldarone. Let me answer your first
question, which was why we use a categorical system of scoring.
The reason we chose a categorical system of scoring is because
it is easily reproducible and can be used across centers. Although
this does lead to some loss of information, this will allow us to
test and validate the score across multiple institutions. We are
actually in the process of accruing patients for a prospectiveThe Journal of Thoracic and Camulti-institutional trial. However, it is important that we also
consider other methods of assessing this score.
Your second question was why all components are scored
equally, and I agree with you that this is something that needs
clarification. For example, a residual VSD in tetrology of Fallot
is an entirely different beast than a residual VSD in primary
VSD repairs. If you had a large residual VSD in tetrology of Fallot,
the patients tend to do worse. Now that we have gathered data for
about 2 to 3 years, we are studying the subcomponents for
each procedure, and we are going to determine which of these
subcomponents is important for each procedure. Hopefully, we
will have the analysis in a year or 2.
Your third question was related to why we did not score residual
lesions that are not intervened on. When we initially started the
score, the plan was to assess the intent to treat, but only the
components that the surgeon operated on were assessed. But I
do agree with you, for example, in a VSD, if after a repair, you
were left with greater than mild tricuspid regurgitation, I think
the score would be inadequate, and we are in the process of
refining the score to reflect this.
Your final question had been about how we used the score to
assess how well we did. We have weekly conferences, and we
review each of the surgeon’s scores and determine how a
procedure that had an inadequate score could have been
performed better. We also have monthly mortality and morbidity
conferences. Currently, we now assign scores for the intraoperative
echocardiograms, and we will compare these with the discharge
echocardiograms. Perhaps that will help us determine when the
intervention needs to be done; thus, this tool could serve not
only as an assessment tool, but also as an interventional tool.
I hope I answered all your questions.
Dr Caldarone. You did.
Dr Francois G. Lacour-Gayet (New York, NY). Dr Nathan, I
enjoyed very much your presentation, and we have followed this
TPS that was initiated by Dr Bacha with great interest. I have a
question of method. How can you predict early death using a
discharge echocardiogram?
Dr Nathan. I know that is an important question. Currently, the
tool is just a retrospective assessment of outcomes based on the
discharge echocardiogram. This is one of the reasons we are taking
more interest in the intraoperative score, because I think the
intraoperative score will be able to help us determine what needs
to be done to prevent mortality.
Glenn Van Arsdell (Toronto, Ontario, Canada). That was a
beautiful study, and I fully agree with it but have a little caveat.
One year ago, we presented a similar controversial report that
suggested if you chase after all these residual lesions in the opera-
ting room, you shift error to the ICU and that the intensive care
performance also affects the outcome. I think back to a book
from your institution in 1994 in which Aldo Castaneda said,
nowhere in the practice of medicine is it more important to have
a harmonious action between many different segments of medi-
cine, intensive care, anesthesia, perfusion, nursing, and so forth.
Why do you suppose in your study we do not see that
importance? It appears in your study that it really is only surgical
performance that matters, not diagnostic performance, not
intensive care performance. In our study, we saw each of those
components being very important.rdiovascular Surgery c Volume 147, Number 1 395
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DDr Nathan. Thank you. I do agree that care in the ICU plays a
role in the ultimate outcome; however, if a procedure is done well,
I think it can mitigate some of these effects. In a previous study, we
had shown that in the stage I population, if they had an optimal
score, it was able to mitigate the effects of preoperative status,
as determined by Pediatric Risk of Mortality scores and also
postoperative status determined by Pediatric Risk of Mortality
and other ICU variables.
Also, although all components shown in this chart are
important for outcomes, I think the TPS perhaps has a more
important role to play. If you can achieve a good operation, I think
you minimize a number of the problems seen in the postoperative
period.
Dr Carl L. Backer (Chicago, Ill). I congratulate you on
using this TPS to try and improve the quality of our outcomes.396 The Journal of Thoracic and Cardiovascular SurgThe question I have is, do you have information about what the
surgeon did with the intraoperative transesophageal echocardio-
graphic results? Your performance score mostly relies on
echocardiographic residual lesions. We use intraoperative
transesophageal echocardiogram to identify residual lesions, and
then, in a certain percentage of our patients, we correct those
residual lesions immediately in the operating room. What
percentage of patients underwent attempts to address those
residual lesions in the operating room at the original procedure
according to an intraoperative transesophageal echocardiogram?
Dr Nathan. We are studying that data now; however,
approximately 3% to 4% had a return to bypass to fix a residual
lesion, and this is mostly related to valve repairs. That is why it
is important that we consider those intraoperative scores and
discharge scores and see what the difference is in outcomes.ery c January 2014
